Name:
Dr Martin Eatock
Job Title:
Consultant / Honorary Senior Lecturer in Medical Oncology
Organisation / Company:
Northern Ireland Cancer Centre
Belfast City Hospital
Biography:
Dr Eatock qualified in medicine from the University of Edinburgh and trained in Oncology in Manchester and Glasgow. He took up post as a Consultant and Honorary Senior Lecturer in Medical Oncology in Belfast in 2000 and is an active member of the Upper Gastro-intestinal, Hepato-pancreatobiliary and Neuro-endocrine tumour teams.
He has clinical and research interests in gastro-intestinal cancer and drug development and is currently chief investigator for a number of national and international clinical trials in upper GI malignancy. Dr Eatock was appointed as Medical Director to the Northern Ireland Cancer Network in 2012 and has overseen the re-development of the Network since then with an expansion in the network site specific groups and the introduction of Peer Review of Cancer MDTs in Northern Ireland.
Name:
Professor Daniel Hochhauser
Job Title:
Chair of Medical Oncology and Consultant Medical Oncologist
Vice Chair:
UK Oncology FORUM
Organisation / Company:
UCL Cancer Institute / UCLH Trust
Biography:
Following postgraduate medical training in London and Oxford he was appointed clinical fellow in medical oncology at the Institute of Molecular Medicine, Oxford where he completed a DPhil. He subsequently worked as a medical oncology fellow at Memorial Sloan Kettering Cancer Center New York before appointment as a senior Lecturer and consultant in 1996.
Professor Hochhauser’s major clinical interest is in gastrointestinal medical oncology. His research is focused on development of novel therapeutics and early phase clinical studies.
Name:
Professor Fiona Thistlethwaite
Post-nominal Letters:
MB BChir PhD MRCP
Job Title:
Medical Oncology Consultant
Biography:
Professor Fiona Thislethwaite MB BChir PhD MRCP is a Medical Oncology Consultant within the ECMT (Experimental Cancer Medicine Team) at The Christie NHS Foundation Trust, an Honorary Professor of Experimental Immunotherapy at The University of Manchester, and the Clinical Director of Manchester CRF at The Christie. Fiona has been actively involved in clinical trial development for many years with a research focus on early phase clinical trials in immune-oncology, particularly adoptive cell therapies, combination immunotherapies and immune biomarkers.
She is Clinical Lead for the Advanced Immune and Cell Therapy Team at The Christie and in 2018 Fiona was pivotal in establishing the iMATCH (Innovate Manchester Advanced Therapy Centre Hub) collaboration which one of three Innovate UK funded ATTC (Advanced Therapy Treatment Centres) forming a network with the aim of scaling up activity in the field of cell and gene therapy.
Name:
Professor Richard Adams
Job Title:
Clinical Senior Lecturer of Oncology & Palliative Medicine
Organisation / Company:
Cardiff University School of Medicine
Biography:
Richard Adams is a reader and Director of the Wales Cancer Trials Unit and Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the NCRI anorectal subgroup and is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD.
He chairs the biomarker development group for FOCUS4 is Chief investigator for FOCUS4 D and leads on the radiotherapy quality assurance for the UK ARISTOTLE, COPERNICUS and TREC trials. He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Cancer Care link with Sierra Leone.
Name:
Professor Richard Wilson
Job Title:
Professor of Gastrointestinal Oncology
Consultant in Medical Oncology
Organisation / Company:
Institute of Cancer Sciences, University of Glasgow
Beatson West of Scotland Cancer Centre
Biography:
Richard Wilson completed his medical degree at the Queen’s University Belfast (QUB) and worked in N. Ireland and Scotland as a junior doctor. He undertook basic science research in colorectal cancer for which he received his doctoral degree. He subsequently trained in clinical oncology in N. Ireland and attained UK accreditation. Following this, he undertook a Fellowship at the National Cancer Institute in the US National Institutes of Health where he received specialist training in medical oncology, early phase cancer clinical trials and drug development.
He returned to the UK as a clinical academic in QUB and the Belfast Health and Social Care Trust. He set up the early phase cancer clinical trials programme in Belfast and the N. Ireland Cancer Trials Network. He moved in February 2019 from his position as Professor in Cancer Medicine in QUB to the University of Glasgow where he is Professor of Gastrointestinal Oncology and also Honorary Consultant in Medical Oncology in the Beatson West of Scotland Cancer Centre.
He works in lower gastrointestinal cancer (mainly in colorectal cancer but also in small bowel cancer and peritoneal malignancies) and conducts biological, translational and clinical research in these diseases. He is Chief Investigator on many local, national and international cancer clinical trials in both early and late phase settings. He previously chaired the UK National Cancer Research Institute Colorectal Cancer Clinical Studies Group and is a member of its Adjuvant and Advanced Disease Subgroup.
Name:
Professor Ruth Plummer
Post-nominal Letters:
MBE FMedSci
Job Title:
Clinical Professor of Experimental Cancer Medicine
Chair:
UK Oncology FORUM
Organisation / Company:
Northern Institute for Cancer Research, Newcastle University
Biography:
Ruth Plummer is Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle University, and an honorary consultant medical oncologist in Newcastle Hospitals Foundation Trust. She is Director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care which is a dedicated clinical trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. She trained at Cambridge and Oxford before moving back home to Newcastle and settling with her family in the Tyne valley.
Her research interests are in the field of DNA repair and early phase clinical trials of novel agents or novel imaging targets. She developed the clinical pharmacodynamic assay used in the first-in-class PARP inhibitor trial in 2003 and has worked with many of the PARP inhibitors currently under clinical development. Her pre-clinical research.
Name:
Professor Sarah Blagden
Job Title
Professor of Experimental Oncology
Organisation / Company:
University of Oxford
Biography:
Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 where she specialised in treating gynaecological cancers, launched Imperial's Early Phase Trial portfolio and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University and is now a Professor of Experimental Oncology. Sarah was Director of the Early Phase Clinical Trials Unit until 2021 when she took over leadership of the Oxford Clinical Trials Office (OCTO) running a national trials portfolio specialising in early phase, Precision Prevention and Early Detection studies. She has been chief or principal investigator for a number of national and international clinical studies and her team's research focus is post-transcriptional gene regulation in precancer progression.
Name:
Dr Anthony Cunliffe
Job Title / Organisation / Company:
Macmillan National Clinical Adviser for Primary Care
Macmillan Lead Clinical Adviser and Clinical Adviser for London
Joint Clinical Chair, South East London Cancer alliance
Biography:
Anthony Cunliffe has been a GP for 17 years and practises part time in South London. He started working for Macmillan Cancer Support in 2012 as a Macmillan GP Facilitator. He subsequently became a GP Advisor and is now the National Lead Medical Adviser and the Clinical Adviser for London. Anthony is also the joint clinical director for the South East London Cancer Alliance and the Oncology Lead at ORCHA. Anthony has experience of working throughout the cancer pathway having been National Prevention and Diagnosis lead at Macmillan and a GPSI in End of Life Care but his passion is to ensure all people living with cancer receive good quality personalised care.
Name:
Dr Caroline Wilson
Job Title:
Honorary Clinical Senior Lecturer
Organisation / Company:
University of Sheffield
Biography:
Caroline graduated with distinction from Sheffield Medical School in 2002 and subsequently completed her junior doctor training in Sheffield, Australia and New Zealand. She began her higher specialist training in Medical Oncology in 2007 and in 2011 she took time out of her clinical training to carry out her PhD in Sheffield Medical School, focusing on the influence of hormones on breast cancer in the bone microenvironment.
After completing her PhD she was appointed as a consultant at Weston Park Cancer Hospital where she specialises in the treatment of breast cancer. Her research time is funded by Sheffield Teaching Hospitals NHS Foundation Trust and focuses on new therapies and therapeutic combinations for breast cancer and breast cancer bone metastases including immune-therapy. She has been primary author and co-author on multiple papers on breast cancer, bisphosphonates and bone metastases published in journals including the Lancet Oncology, Annals of Oncology, Clinical Cancer Research, JAMA oncology. She is also a reviewer for several journals.
Name:
Dr Marina Parton
Job Title:
Medical Oncologist
Organisation / Company:
The Royal Marsden and Kingston Hospital
Biography:
Dr Marina Parton is a Medical Oncologist in Breast Cancer at The Royal Marsden and Kingston Hospital. Appointed to The Royal Marsden Consultant Body in 2009, she received her oncology training at The Royal Marsden and carried out her research in neoadjuvant therapy in breast cancer as part of a MD at The Institute of Cancer Research with Professors Dowsett and Smith.
Dr Parton is Lead Cancer Clinician in The Royal Marsden’s satellite chemotherapy unit, a joint venture with Kingston Hospital and Macmillan Cancer Support as well as leading breast clinics at The Royal Marsden in Chelsea. She has published in breast cancer research, and is principle investigator in a number of clinical trials at The Royal Marsden and Kingston Hospital. She has previously been Chair of the Acute Oncology Group at The Royal Marsden, part of the Breast Pathway Group at London Cancer Alliance (LCA) and co chair of the LCA Chemotherapy Closer to Home Group. She is involved in a number of national educational groups and meetings in early and secondary breast cancer, and co edited Breast Cancer Survivorship; consequences of early breast cancer treatment. Dr Parton was member of the NICE Early Breast Guidelines update (published 2018).
Name:
Dr Vicky Coyle
Job Title:
Senior Lecturer and Honorary Consultant
Organisation / Company:
Centre for Cancer Research and Cell Biology, Queen’s University Belfast
Biography:
Senior Lecturer and Honorary Consultant in Medical Oncology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast.
Vicky Coyle is a senior lecturer in Queens University Belfast and a consultant medical oncologist in the Belfast Trust. Her research interests include early phase clinical trials, late phase trials in supportive care in oncology and translational research and clinical trials in colorectal cancer.
Name:
Professor Samreen Ahmed
Post-nominal Letters:
FRCP, MD, MBBS, MSc (onc)
Job Title:
Consultant in Medical Oncology
Organisation / Company:
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
Biography:
Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester in 2016.
Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group. Honorary secretary for Association of Cancer Physicians since 2019.
Name:
Dr Pippa Corrie
Post-nominal Letters:
PhD FRCP
Job Title:
Consultant Medical Oncologist and Affiliated Associate Professor
Organisation / Company:
University of Cambridge
Biography:
Pippa Corrie qualified in medicine at Oxford University, having previously undertaken a PhD in anti-cancer drug development. She has been a Consultant Medical Oncologist at Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital) since 1997 and is an Associate Lecturer in the University of Cambridge. She has over 25 years of experience leading a regional melanoma clinical service highly integrated with research and been directly involved in development of modern melanoma therapeutics, She previously chaired the NCRI skin cancer group and is a co-founder and Trustee of the UK national charity, Melanoma Focus. Pippa works regionally, nationally and internationally to conduct melanoma clinical and translational trials: she is currently Chief Investigator of the NIHR portfolio MITRE microbiome study and PREMIUM, evaluating neoadjuvant BRAF targeted therapy. She is the NIHR Clinical Research Network National Specialty Lead for Late Phase and International Cancer Trials.
Name:
Dr David Chang
Job Title:
Professor of Surgical Oncology
Organisation / Company:
University of Glasgow
Biography:
Dr David Chang is a Reader in Surgery at University of Glasgow. His research focus on the development and implementation of novel therapeutic strategies for pancreatic cancer particularly around DNA-damage response deficiency, by utilising molecular biomarkers of therapeutic response. Dr Chang undertook his pancreatic surgical fellowship, PhD, and post-doctoral training in Australia. He was recruited to University of Glasgow in 2013, as part of an initiative to implement precision medicine in Scotland and the UK. He co-leads Precision-Panc, a Cancer Research UK precision medicine programme to deliver personalised cancer care for pancreatic cancer, and is the overall translational lead. Dr Chang is also involved in the Precision Promise, a Pancreatic Cancer Action Network (USA) precision medicine initiative. He also contributes to ICGC-ARGO, aiming to shape the future of the next generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.
Clinically Dr Chang is a Consultant Pancreatic Surgeon at the West of Scotland Pancreatic Unit in Glasgow Royal Infirmary, a tertiary pancreatic referral centre for the West of Scotland. As a surgeon scientist, he aims to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation.
Name:
Professor Nick Van As
Job Title:
Medical Director and Consultant Clinical Oncologist in Urology.
Organisation / Company:
The Royal Marsden
Biography:
Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology.
Dr Nicholas van As was appointed Medical Director of The Royal Marsden in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit in the hospital for eight years and is Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI and he has published numerous papers on these subjects and delivered presentations at international meetings.
He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided Radiotherapy (IGRT) and surgery for treating prostate cancer.
Name:
Dr Lisa Pickering
Job Title:
Consultant Medical Oncologist, Renal and Skin Cancers
Associate Medical Director for Strategy
Organisation / Company:
The Royal Marsden NHS Foundation Trust
Biography:
Dr Lisa Pickering is a Consultant Medical Oncologist who specialises in the treatment of cancers of the urinary tract; prostate cancer, bladder cancer, penile cancer, ureteric cancer and renal cancer.
Dr Pickering qualified in Medicine from at the Universities of Oxford (1989-1992) and London (1992-1995). She trained in Medical Oncology at Guy’s and St. Thomas’ and St. George’s Hospitals and was awarded a PhD from the University of London in 2007.
She was appointed as a Consultant Medical Oncologist at St. George’s Hospital and the Royal Marsden in 2008. In 2011 she became Clinical Lead for Oncology at St. George’s and in 2015 was appointed Chair of the Division of Medicine and Cardiovascular Sciences. She is research lead for urology at St. George’s and is a member of the UK National Clinical Study Groups for penile, renal and bladder cancers. In these roles she is involved in participating and leading numerous clinical and translational research protocols.
Name:
Professor Peter Hoskin
Job Title / Organisation / Company:
Consultant in Clinical Oncology
Mount Vernon Cancer Centre
Professor in Clinical Oncology
University of Manchester
Honorary Consultant in Clinical Oncology
Christie Hospital & University College Hospital
Biography:
Peter Hoskin trained in clinical oncology at the Royal Marsden Hospital London and has been consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood UK since 1992. He is also Professor in Clinical Oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester and University College Hospital, London. Research interests focus on radiosensitisation, biomarkers, radiotherapy quality assurance, palliative radiotherapy, and brachytherapy. He is a member of the GEC ESTRO committee and ESTRO Board. In the UK chairs the Fellowship Examination Board and the Academic Committee for the Royal College of Radiologists. He has published extensively and was Editor of Clinical Oncology for 15 years. He is now Clinical Editor for Radiotherapy and Oncology and sits on several journal editorial boards.
Name:
Professor Ananya Choudhury
Job Title:
Chair and Honorary Consultant in Clinical Oncology
Group Leader Translational Radiobiology
Organisation / Company:
The Christie NHS Foundation Trust.
Biography:
Professor Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. Within the Division of Cancer Sciences, The University of Manchester, she is clinical lead for advanced radiotherapy, including the MRLinac project, and is co-Group Leader of The Translational Radiobiology Group
Professor Choudhury graduated from Trinity College, Cambridge, but undertook her Clinical Oncology training at the Yorkshire Deanery from 2000-2008. Between 2005 and 2007, she was a Cancer Research UK Clinical Training Research Fellow and she undertook her PhD at the University of Leeds and Princess Margaret Hospital in Toronto, Canada. She has a lead role in education and training for specialist registrars and clinical fellows.
Over the past few years, Professor Choudhury has been involved with national concerns such as the Royal College of Radiologists, the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad), the NCRI Bladder Clinical Studies Group and the National Institute of Health and Care Excellence (NICE). Since early 2021, she has been the Editor in Chief of Clinical Oncology.
Name:
Professor Benjamin Fairfax
Post-nominal Letters:
BM BCh PhD MRCP
Job Title:
Associate Professor
Hon. Consultant Medical Oncologist
Organisation / Company:
University of Oxford
Biography:
I did my PhD at the MRC-LMCB, UCL completing this in 2003 and then completed my clinical training in Oxford.
I was accepted onto the Oxford Academic Foundation programme and, having become interested in human genetics, took time away from clinical training to gain postdoctoral experience. I was awarded a Wellcome MB-PhD postdoctoral Fellowship and I did this in Julian Knight's group at the Wellcome Centre for Human Genetics.
Upon completion of this I specialised in Medical Oncology. I see skin cancer patients as a Consultant in the Oxford Cancer Centre. I am co-lead for Immunology on the NIHR Oncology Translational Research Group.
Name:
Dr. Claudia AM Fulgenzi
Job Title:
Locum Consultant in Oncology
Organisation / Company:
Chelsea and Westminster Hospital
Biography:
Dr. Claudia AM Fulgenzi started her academic journey by earning a degree in medicine from the University of Rome Tor Vergata in Rome in 2017. Following her graduation, she pursued specialized training in Oncology at the University Campus Bio Medico of Rome in Italy. During this period, Dr. Fulgenzi honed her clinical expertise and developed a particular interest in gastrointestinal (GI) cancers, with a specific focus on hepatic-biliary malignancies.
In pursuit of further knowledge, Dr. Fulgenzi made the decision to move to London in 2021. After joining the esteemed academic community at Imperial College as research fellow, she was offered a PhD program focused on cancer-immunotherapy in October 2022.
In 2022, Dr. Fulgenzi was bestowed with the ASCO Merit Award, a prestigious recognition from the American Society of Clinical Oncology and with the Young Investigator award by the International Liver Cancer Association (ILCA) for her research in liver cancer. The following year, in 2023, she received a merit award by the American Society of Clinical Oncology as leading author of a sub-analysis of the IMbrave150 trial presented at the ASCO GI symposium, further solidifying her reputation as a rising star in the field of gastrointestinal oncology.
Simultaneously, Dr. Fulgenzi has been actively involved in clinical practice, serving as a Locum Consultant in Oncology at Chelsea and Westminster Hospital. In this role, she provides expert medical guidance and comprehensive care to patients battling cancer. Driven by a patient-centred approach, she strives to improve treatment outcomes and enhance the quality of life for those under her care.
Name:
Professor Russell Petty
Post-nominal Letters:
BMSc MB ChB PhD MRCP(UK) MRCPE FRCP
Job Title:
Chair of Medical Oncology
Director of Tayside Medical Science Centre(TASC)
Organisation / Company:
Ninewells Hospital and Medical School, University of Dundee
Biography:
Professor Russell Petty is Chair of Medical Oncology and Deputy Head of the Division of Molecular and Clinical Medicine at the University of Dundee. He leads a research programme in clinical and translational cancer medicine focused upon oesophageal and gastric cancer involving both laboratory research developing precision medicine approaches and investigating mechanisms of drug resistance , as well as early and late phase clinical trials. His government and professional advisory roles include to the Chief Medical Officer in Scotland, Scottish Parliament, Chief Scientist in Scotland, National Cancer Research Institute, National Institute of Health and Clinical Excellence, Scottish Medicines Consortium, European Organisation for Research and Treatment of Cancer, European Society of Medical Oncology, International Gastric Cancer Association and International Cancer Genome Consortium-ARGO. Professor Petty has over 90 peer-reviewed publications, including in high impact journals such as The Lancet, The Lancet Oncology, Journal of Clinical Oncology, and Nature Genetics.
Name:
Dr Janet Graham
Job Title:
Consultant Medical Oncologist
Organisation / Company:
The Beatson West of Scotland Cancer Centre
Biography:
Dr Janet Graham
Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow, UK
Dr Graham is a Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre where she treats colon, pancreas and upper gastrointestinal (GI) cancers. Along with being GI team lead, her main focus is on maximising patient opportunities to take part in clinical trials; she is chief or principle investigator on a number of early and later phase clinical trials. Dr Graham is also Clinical Lead for the West of Scotland Colorectal Cancer Managed Clinical Network and she currently chairs the NCRI Adjuvant and Advanced Colorectal Subgroup. She is a medical advisor to Bowel Cancer UK and advises NICE and SMC on new medicines in GI indications. She sits on a number of trial management groups including FOCUS 4, ADD ASPIRIN, ARIEL, FoxTROT 2&3 and leads the PRIMUS 001 trial in the UK, which is part of the PRECISION PANC platform. She is on the faculty for Oncology Forum, where she co-chairs the upper GI session. Dr Graham has worked hard over recent years to ensure equitable access to BRAF, RAS and MSI testing for colorectal patients along with HER2 testing for gastric cancer. She has a key role in education at the Beatson where she is the lead trainer for IMTs, and she also supports the undergraduate programme and is clinical supervisor for medical oncology trainees in GI cancers.
Name:
Professor Peter Hoskin
Job Title / Organisation / Company:
Consultant in Clinical Oncology
Mount Vernon Cancer Centre
Professor in Clinical Oncology
University of Manchester
Honorary Consultant in Clinical Oncology
Christie Hospital & University College Hospital
Biography:
Peter Hoskin trained in clinical oncology at the Royal Marsden Hospital London and has been consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood UK since 1992. He is also Professor in Clinical Oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester and University College Hospital, London. Research interests focus on radiosensitisation, biomarkers, radiotherapy quality assurance, palliative radiotherapy, and brachytherapy. He is a member of the GEC ESTRO committee and ESTRO Board. In the UK chairs the Fellowship Examination Board and the Academic Committee for the Royal College of Radiologists. He has published extensively and was Editor of Clinical Oncology for 15 years. He is now Clinical Editor for Radiotherapy and Oncology and sits on several journal editorial boards.
Name:
Professor Ananya Choudhury
Job Title:
Chair and Honorary Consultant in Clinical Oncology
Group Leader Translational Radiobiology
Organisation / Company:
The Christie NHS Foundation Trust.
Biography:
Professor Choudhury is Chair and Honorary Consultant in Clinical Oncology. She joined The Christie in 2008 specialising in urology and sarcoma and has a strong interest in translational research. In 2013, she decided to focus on radiotherapy-related research in prostate and bladder cancers. Within the Division of Cancer Sciences, The University of Manchester, she is clinical lead for advanced radiotherapy, including the MRLinac project, and is co-Group Leader of The Translational Radiobiology Group
Professor Choudhury graduated from Trinity College, Cambridge, but undertook her Clinical Oncology training at the Yorkshire Deanery from 2000-2008. Between 2005 and 2007, she was a Cancer Research UK Clinical Training Research Fellow and she undertook her PhD at the University of Leeds and Princess Margaret Hospital in Toronto, Canada. She has a lead role in education and training for specialist registrars and clinical fellows.
Over the past few years, Professor Choudhury has been involved with national concerns such as the Royal College of Radiologists, the National Cancer Research Institute (NCRI) Clinical and Translational Radiotherapy Research Working Group (CTRad), the NCRI Bladder Clinical Studies Group and the National Institute of Health and Care Excellence (NICE). Since early 2021, she has been the Editor in Chief of Clinical Oncology.
Name:
Dr Marina Parton
Job Title:
Medical Oncologist
Organisation / Company:
The Royal Marsden and Kingston Hospital
Biography:
Dr Marina Parton is a Medical Oncologist in Breast Cancer at The Royal Marsden and Kingston Hospital. Appointed to The Royal Marsden Consultant Body in 2009, she received her oncology training at The Royal Marsden and carried out her research in neoadjuvant therapy in breast cancer as part of a MD at The Institute of Cancer Research with Professors Dowsett and Smith.
Dr Parton is Lead Cancer Clinician in The Royal Marsden’s satellite chemotherapy unit, a joint venture with Kingston Hospital and Macmillan Cancer Support as well as leading breast clinics at The Royal Marsden in Chelsea. She has published in breast cancer research, and is principle investigator in a number of clinical trials at The Royal Marsden and Kingston Hospital. She has previously been Chair of the Acute Oncology Group at The Royal Marsden, part of the Breast Pathway Group at London Cancer Alliance (LCA) and co chair of the LCA Chemotherapy Closer to Home Group. She is involved in a number of national educational groups and meetings in early and secondary breast cancer, and co edited Breast Cancer Survivorship; consequences of early breast cancer treatment. Dr Parton was member of the NICE Early Breast Guidelines update (published 2018).
Name:
Dr Vicky Coyle
Job Title:
Senior Lecturer and Honorary Consultant
Organisation / Company:
Centre for Cancer Research and Cell Biology, Queen’s University Belfast
Biography:
Senior Lecturer and Honorary Consultant in Medical Oncology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast.
Vicky Coyle is a senior lecturer in Queens University Belfast and a consultant medical oncologist in the Belfast Trust. Her research interests include early phase clinical trials, late phase trials in supportive care in oncology and translational research and clinical trials in colorectal cancer.
Name:
Professor Samreen Ahmed
Post-nominal Letters:
FRCP, MD, MBBS, MSc (onc)
Job Title:
Consultant in Medical Oncology
Organisation / Company:
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
Biography:
Professor Ahmed has been a Consultant in Medical Oncology since 2006 and qualified in 1994 at the Royal Free Hospital School of Medicine, London. She has a research degree (MD) through Nottingham University and undertook oncology training in Weston Park Hospital (Sheffield), Nottingham City Hospital and the Leicester Royal Infirmary. She is a Fellow of the Royal College of Physicians. Appointed Honorary Chair of Medical Oncology by University of Leicester in 2016.
Professor Ahmed is the Training Programme Director for Medical Oncology. She is Chief Investigator and local Principal Investigator for a number of clinical trials in breast and lung cancer. Member of NCRI lung CSG and BTOG Steering Group. Honorary secretary for Association of Cancer Physicians since 2019.
Name:
Dr Pippa Corrie
Post-nominal Letters:
PhD FRCP
Job Title:
Consultant Medical Oncologist and Affiliated Associate Professor
Organisation / Company:
University of Cambridge
Biography:
Pippa Corrie qualified in medicine at Oxford University, having previously undertaken a PhD in anti-cancer drug development. She has been a Consultant Medical Oncologist at Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital) since 1997 and is an Associate Lecturer in the University of Cambridge. She has over 25 years of experience leading a regional melanoma clinical service highly integrated with research and been directly involved in development of modern melanoma therapeutics, She previously chaired the NCRI skin cancer group and is a co-founder and Trustee of the UK national charity, Melanoma Focus. Pippa works regionally, nationally and internationally to conduct melanoma clinical and translational trials: she is currently Chief Investigator of the NIHR portfolio MITRE microbiome study and PREMIUM, evaluating neoadjuvant BRAF targeted therapy. She is the NIHR Clinical Research Network National Specialty Lead for Late Phase and International Cancer Trials.
Name:
Dr David Chang
Job Title:
Professor of Surgical Oncology
Organisation / Company:
University of Glasgow
Biography:
Dr David Chang is a Reader in Surgery at University of Glasgow. His research focus on the development and implementation of novel therapeutic strategies for pancreatic cancer particularly around DNA-damage response deficiency, by utilising molecular biomarkers of therapeutic response. Dr Chang undertook his pancreatic surgical fellowship, PhD, and post-doctoral training in Australia. He was recruited to University of Glasgow in 2013, as part of an initiative to implement precision medicine in Scotland and the UK. He co-leads Precision-Panc, a Cancer Research UK precision medicine programme to deliver personalised cancer care for pancreatic cancer, and is the overall translational lead. Dr Chang is also involved in the Precision Promise, a Pancreatic Cancer Action Network (USA) precision medicine initiative. He also contributes to ICGC-ARGO, aiming to shape the future of the next generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.
Clinically Dr Chang is a Consultant Pancreatic Surgeon at the West of Scotland Pancreatic Unit in Glasgow Royal Infirmary, a tertiary pancreatic referral centre for the West of Scotland. As a surgeon scientist, he aims to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation.
Name:
Professor Nick Van As
Job Title:
Medical Director and Consultant Clinical Oncologist in Urology.
Organisation / Company:
The Royal Marsden
Biography:
Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology.
Dr Nicholas van As was appointed Medical Director of The Royal Marsden in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit in the hospital for eight years and is Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI and he has published numerous papers on these subjects and delivered presentations at international meetings.
He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided Radiotherapy (IGRT) and surgery for treating prostate cancer.
Name:
Professor Nick Van As
Job Title:
Medical Director and Consultant Clinical Oncologist in Urology.
Organisation / Company:
The Royal Marsden
Biography:
Medical Director of The Royal Marsden and Consultant Clinical Oncologist in Urology.
Dr Nicholas van As was appointed Medical Director of The Royal Marsden in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit in the hospital for eight years and is Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI and he has published numerous papers on these subjects and delivered presentations at international meetings.
He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided Radiotherapy (IGRT) and surgery for treating prostate cancer.
Name:
Dr Anthony Cunliffe
Job Title / Organisation / Company:
Macmillan National Clinical Adviser for Primary Care
Macmillan Lead Clinical Adviser and Clinical Adviser for London
Joint Clinical Chair, South East London Cancer alliance
Biography:
Anthony Cunliffe has been a GP for 17 years and practises part time in South London. He started working for Macmillan Cancer Support in 2012 as a Macmillan GP Facilitator. He subsequently became a GP Advisor and is now the National Lead Medical Adviser and the Clinical Adviser for London. Anthony is also the joint clinical director for the South East London Cancer Alliance and the Oncology Lead at ORCHA. Anthony has experience of working throughout the cancer pathway having been National Prevention and Diagnosis lead at Macmillan and a GPSI in End of Life Care but his passion is to ensure all people living with cancer receive good quality personalised care.
Name:
Dr Caroline Wilson
Job Title:
Honorary Clinical Senior Lecturer
Organisation / Company:
University of Sheffield
Biography:
Caroline graduated with distinction from Sheffield Medical School in 2002 and subsequently completed her junior doctor training in Sheffield, Australia and New Zealand. She began her higher specialist training in Medical Oncology in 2007 and in 2011 she took time out of her clinical training to carry out her PhD in Sheffield Medical School, focusing on the influence of hormones on breast cancer in the bone microenvironment.
After completing her PhD she was appointed as a consultant at Weston Park Cancer Hospital where she specialises in the treatment of breast cancer. Her research time is funded by Sheffield Teaching Hospitals NHS Foundation Trust and focuses on new therapies and therapeutic combinations for breast cancer and breast cancer bone metastases including immune-therapy. She has been primary author and co-author on multiple papers on breast cancer, bisphosphonates and bone metastases published in journals including the Lancet Oncology, Annals of Oncology, Clinical Cancer Research, JAMA oncology. She is also a reviewer for several journals.
Name:
Professor Benjamin Fairfax
Post-nominal Letters:
BM BCh PhD MRCP
Job Title:
Associate Professor
Hon. Consultant Medical Oncologist
Organisation / Company:
University of Oxford
Biography:
I did my PhD at the MRC-LMCB, UCL completing this in 2003 and then completed my clinical training in Oxford.
I was accepted onto the Oxford Academic Foundation programme and, having become interested in human genetics, took time away from clinical training to gain postdoctoral experience. I was awarded a Wellcome MB-PhD postdoctoral Fellowship and I did this in Julian Knight's group at the Wellcome Centre for Human Genetics.
Upon completion of this I specialised in Medical Oncology. I see skin cancer patients as a Consultant in the Oxford Cancer Centre. I am co-lead for Immunology on the NIHR Oncology Translational Research Group.
Name:
Dr. Claudia AM Fulgenzi
Job Title:
Locum Consultant in Oncology
Organisation / Company:
Chelsea and Westminster Hospital
Biography:
Dr. Claudia AM Fulgenzi started her academic journey by earning a degree in medicine from the University of Rome Tor Vergata in Rome in 2017. Following her graduation, she pursued specialized training in Oncology at the University Campus Bio Medico of Rome in Italy. During this period, Dr. Fulgenzi honed her clinical expertise and developed a particular interest in gastrointestinal (GI) cancers, with a specific focus on hepatic-biliary malignancies.
In pursuit of further knowledge, Dr. Fulgenzi made the decision to move to London in 2021. After joining the esteemed academic community at Imperial College as research fellow, she was offered a PhD program focused on cancer-immunotherapy in October 2022.
In 2022, Dr. Fulgenzi was bestowed with the ASCO Merit Award, a prestigious recognition from the American Society of Clinical Oncology and with the Young Investigator award by the International Liver Cancer Association (ILCA) for her research in liver cancer. The following year, in 2023, she received a merit award by the American Society of Clinical Oncology as leading author of a sub-analysis of the IMbrave150 trial presented at the ASCO GI symposium, further solidifying her reputation as a rising star in the field of gastrointestinal oncology.
Simultaneously, Dr. Fulgenzi has been actively involved in clinical practice, serving as a Locum Consultant in Oncology at Chelsea and Westminster Hospital. In this role, she provides expert medical guidance and comprehensive care to patients battling cancer. Driven by a patient-centred approach, she strives to improve treatment outcomes and enhance the quality of life for those under her care.
Name:
Dr Lisa Pickering
Job Title:
Consultant Medical Oncologist, Renal and Skin Cancers
Associate Medical Director for Strategy
Organisation / Company:
The Royal Marsden NHS Foundation Trust
Biography:
Dr Lisa Pickering is a Consultant Medical Oncologist who specialises in the treatment of cancers of the urinary tract; prostate cancer, bladder cancer, penile cancer, ureteric cancer and renal cancer.
Dr Pickering qualified in Medicine from at the Universities of Oxford (1989-1992) and London (1992-1995). She trained in Medical Oncology at Guy’s and St. Thomas’ and St. George’s Hospitals and was awarded a PhD from the University of London in 2007.
She was appointed as a Consultant Medical Oncologist at St. George’s Hospital and the Royal Marsden in 2008. In 2011 she became Clinical Lead for Oncology at St. George’s and in 2015 was appointed Chair of the Division of Medicine and Cardiovascular Sciences. She is research lead for urology at St. George’s and is a member of the UK National Clinical Study Groups for penile, renal and bladder cancers. In these roles she is involved in participating and leading numerous clinical and translational research protocols.
Name:
Professor Russell Petty
Post-nominal Letters:
BMSc MB ChB PhD MRCP(UK) MRCPE FRCP
Job Title:
Chair of Medical Oncology
Director of Tayside Medical Science Centre(TASC)
Organisation / Company:
Ninewells Hospital and Medical School, University of Dundee
Biography:
Professor Russell Petty is Chair of Medical Oncology and Deputy Head of the Division of Molecular and Clinical Medicine at the University of Dundee. He leads a research programme in clinical and translational cancer medicine focused upon oesophageal and gastric cancer involving both laboratory research developing precision medicine approaches and investigating mechanisms of drug resistance , as well as early and late phase clinical trials. His government and professional advisory roles include to the Chief Medical Officer in Scotland, Scottish Parliament, Chief Scientist in Scotland, National Cancer Research Institute, National Institute of Health and Clinical Excellence, Scottish Medicines Consortium, European Organisation for Research and Treatment of Cancer, European Society of Medical Oncology, International Gastric Cancer Association and International Cancer Genome Consortium-ARGO. Professor Petty has over 90 peer-reviewed publications, including in high impact journals such as The Lancet, The Lancet Oncology, Journal of Clinical Oncology, and Nature Genetics.
Name:
Dr Janet Graham
Job Title:
Consultant Medical Oncologist
Organisation / Company:
The Beatson West of Scotland Cancer Centre
Biography:
Dr Janet Graham
Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow, UK
Dr Graham is a Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre where she treats colon, pancreas and upper gastrointestinal (GI) cancers. Along with being GI team lead, her main focus is on maximising patient opportunities to take part in clinical trials; she is chief or principle investigator on a number of early and later phase clinical trials. Dr Graham is also Clinical Lead for the West of Scotland Colorectal Cancer Managed Clinical Network and she currently chairs the NCRI Adjuvant and Advanced Colorectal Subgroup. She is a medical advisor to Bowel Cancer UK and advises NICE and SMC on new medicines in GI indications. She sits on a number of trial management groups including FOCUS 4, ADD ASPIRIN, ARIEL, FoxTROT 2&3 and leads the PRIMUS 001 trial in the UK, which is part of the PRECISION PANC platform. She is on the faculty for Oncology Forum, where she co-chairs the upper GI session. Dr Graham has worked hard over recent years to ensure equitable access to BRAF, RAS and MSI testing for colorectal patients along with HER2 testing for gastric cancer. She has a key role in education at the Beatson where she is the lead trainer for IMTs, and she also supports the undergraduate programme and is clinical supervisor for medical oncology trainees in GI cancers.